Business
Philip Morris International Urges U.S. Food and Drug Administration Advisory Committee to Recommend Continued Marketing of IQOS as Modified Risk Product
STAMFORD, CT, October 08, 2025--Experts from Philip Morris International Inc. (NYSE: PM) presented evidence to the Tobacco Products Scientific Advisory Committee (TPSAC). The committee, comprised of independent scientific researchers, provides nonbinding recommendations to the U.S. Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP).
About this update from Philip Morris International Inc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3543,"height":612,"url":"https://media.zenfs.com/en/business-wire.com/eab67409f99698c330c71ca38701de2d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/j4oQZSqH_EaBgy1E0Rv_OA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE2NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/eab67409f99698c330c71ca38701de2d","width":960,"height":166},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/YHsAZYZR2Bz3zruNEVCskA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00MTQ7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/eab67409f99698c330c71ca38701de2d","width":1200,"height":207}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"A pioneer in modified risk tobacco products, Philip Morris International is the only company to have received a modified risk marketing claim for an electronic nicotine device.","length":176,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":176,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"FDA concludes "Evidence continues to support the modified exposure claim that ‘Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals.’"","length":282,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":282,"olType":false},{"type":"text","content":"STAMFORD, CT, October 08, 2025--(BUSINESS WIRE)--Experts from Philip Morris International Inc. (NYSE: PM) presented evidence to the Tobacco Products Scientific Advisory Committee (TPSAC). The committee, comprised of independent scientific researchers, provides nonbinding recommendations to the U.S. Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP).","length":371,"tagName":"p"},{"type":"text","content":"The full-day meeting on October 7 was part of the FDA’s customary review of PMI’s request to continue marketing versions of its IQOS heated tobacco products in the U.S. as modified risk tobacco products (MRTPs), a necessary step while FDA completes its review of pending applications for IQOS ILUMA (a later version of the IQOS models that are currently authorized by the FDA) to reach and transition even...